History and Development of the Society of Heart Failure Specialists (On the 25th Anniversary of the Society)
https://doi.org/10.18087/cardio.2024.11.n2839
Abstract
During the 25 years of the existence of the Russian Society of Experts in Heart Failure, it has become the most numerous and authoritative medical association. The Society has representative offices in 52 regions of Russia, and its active members amount to more than 4,000 various specialists. More than 200 Schools, regional conferences, and annual Congresses have been held annually. Dozens of clinical studies have been performed under the auspices of the Society, and the Cardiology journal has been published. This article also outlines the following new promising areas for the development of the Society: widespread introduction of modern clinical guidelines into clinical practice; transition to personalized medicine based on phenotyping of patients with heart failure; acceleration of heart failure diagnostics and earlier initiation of treatment with recommended doses; transition to remote follow-up of heart failure outpatients.
Keywords
Heart failure,
heart failure phenotypes,
personalized medicine,
metabolomic clusters of heart failure
Supporting agencies: No conflict of interest is reported.
About the Author
Yu. N. Belenkov
Sechenov First Moscow State Medical University, Department and Clinic of Hospital Therapy #1 of the Sklifosovsky Institute of Clinical Medicine, Moscow
Russian Federation
Russian Federation
Head of the Department of Hospital Therapy No. 1 of the N.V. Sklifosovsky Institute of Clinical Medicine, Doctor of Medical Sciences, Professor, Academician of the Russian Academy of Sciences
References
1. Ondetti MA, Williams NJ, Sabo E, Pluscec J, Weaver ER, Kocy O. Angiotensin-converting enzyme inhibitors from the venom of Bothrops jararaca. Isolation, elucidation of structure, and synthesis. Biochemis try. 1971;10(22):4033–9. DOI: 10.1021/bi00798a004
2. Turini Gustave A, Brunner Hans R, Gribic M, Waeber B, Gavras H. Improvement of chronic congestive heart-failure by oral captopril. The Lancet. 1979;313(8128):1213–5. DOI: 10.1016/S0140 6736(79)91897-X
3. The Consensus Trial Study Group*. Effects of Enalapril on Mortality in Severe Congestive Heart Failure. New England Journal of Medicine. 1987;316(23):1429–35. DOI: 10.1056/NEJM198706043162301
4. The SOLVD Investigators*, Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN. Effect of Enalapril on Survival in Patients with Reduced Left Ventricular Ejection Fractions and Congestive Heart Failure. New England Journal of Medicine. 1991;325(5):293–302. DOI: 10.1056/NEJM199108013250501
5. Mareev V.Yu. Pharmacoeconomic evaluation of the use of ACE-I in ambulatory patients with heart failure (FASON). Russian Heart Failure Journal. 2002;3(1):38–9.
6. Sweet CS, Rucinska EJ. Losartan in Heart Failure: Preclinical Experiences and Initial Clinical Outcomes. European Heart Journal. 1994;15(Suppl D):139–44. DOI: 10.1093/eurheartj/15.suppl_D.139
7. Rationale, design, implementation, and baseline characteristics of patients in the dig trial: A large, simple, long-term trial to evaluate the effect of digitalis on mortality in heart failure. Controlled Clinical Trials. 1996;17(1):77–97. DOI: 10.1016/0197-2456(95)00065-8
8. Packer M, Colucci WS, Sackner-Bernstein JD, Liang C, Goldscher DA, Freeman I et al. Double-Blind, Placebo-Controlled Study of the Effects of Carvedilol in Patients With Moderate to Severe Heart Failure: The PRECISE Trial. Circulation. 1996;94(11):2793–9. DOI: 10.1161/01.CIR.94.11.2793
9. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF). Lancet. 1999;353(9169):2001–7. DOI: 10.1016/S0140-6736(99)04440-2
10. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353(9146):9–13. PMID: 10023943
11. Mareev V.Yu., Danielyan M.O. Optimizing the use of BEtaloc ZOK in patients with CHF in routine medical practicE. Design and results of the study BEZE. Russian Heart Failure Journal. 2005;6(6):251–7.
12. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A et al. The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure. New England Journal of Medicine. 1999;341(10):709–17. DOI: 10.1056/NEJM199909023411001
13. Heart Failure Matters. Practical information for patients, families and caregivers. Available at: https://www.heartfailurematters.org/ru/
14. Polyakov D.S., Fomin I.V., Belenkov Yu.N., Mareev V.Yu., Ageev F.T., Artemjeva E.G. et al. Chronic heart failure in the Russian Federation: what has changed over 20 years of follow-up? Results of the EPOCH CHF study. Kardiologiia. 2021;61(4):4–14. DOI: 10.18087/cardio.2021.4.n1628
15. Belenkov Yu.N., Ageev F.T., Banshchikov G.T., Volkova E.G., Gilyarevsky S.R., Mareev V.Yu. The influence of specialized forms of active outpatient management on the functional status, quality of life and hemodynamic parameters of patients with severe heart failure. Results of the Russian program ‘Chance’. Russian Heart Failure Jour nal. 2007;8(3):112–6.
16. Shlyakhto E.V., Belenkov Yu.N., Boytsov S.A., Villevalde S.V., Galyavich A.S., Glezer M.G. et al. Interim analysis of a prospective observational multicenter registry study of patients with chronic heart failure in the Russian Federation ‘PRIORITET-CHF’: initial characteristics and treatment of the first included patients. Russian Journal of Cardiology. 2023;28(10):93–103. DOI: 10.15829/1560-4071-2023-5593
17. Seferovic PM, Coats AJS, Filippatos G. The ESC Textbook of Heart Failure: breaking the new educational frontier. European Heart Journal. 2024;ehad897. [Epub ahead of print]. DOI: 10.1093/eurheartj/ehad897
18. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal. 2023;44(37):3627–39. DOI: 10.1093/eurheartj/ehad195
19. Vaduganathan M, Claggett BL, Jhund PS, Cunningham JW, Pedro Ferreira J, Zannad F et al. Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. The Lancet. 2020;396(10244):121–8. DOI: 10.1016/S0140-6736(20)30748-0
20. Mebazaa A, Davison B, Chioncel O, Cohen-Solal A, Diaz R, Filippatos G et al. Safety, tolerability and efficacy of up-titration of guide line-directed medical therapies for acute heart failure (STRONG HF): a multinational, open-label, randomised, trial. The Lancet. 2022;400(10367):1938–52. DOI: 10.1016/S0140-6736(22)02076-1
21. Triposkiadis F, Butler J, Abboud FM, Armstrong PW, Adamopoulos S, Atherton JJ et al. The continuous heart failure spectrum: moving beyond an ejection fraction classification. European Heart Journal. 2019;40(26):2155–63. DOI: 10.1093/eurheartj/ehz158
22. Lam CSP, Arnott C, Beale AL, Chandramouli C, Hilfiker-Kleiner D, Kaye DM et al. Sex differences in heart failure. European Heart Journal. 2019;40(47):3859–3868c. DOI: 10.1093/eurheartj/ehz835
23. Cubbon RM, Lyon AR. Cardio-oncology: Concepts and practice. Indian Heart Journal. 2016;68 Suppl 1(Suppl 1):S77–85. DOI: 10.1016/j.ihj.2016.01.022
24. Nagamine T, Gillette B, Pakhomov A, Kahoun J, Mayer H, Burghaus R et al. Multiscale classification of heart failure phenotypes by unsupervised clustering of unstructured electronic medical record data. Scientific Reports. 2020;10(1):21340. DOI: 10.1038/s41598-020-77286-6
25. Marx N, Federici M, Schütt K, Müller-Wieland D, Ajjan RA, An tunes MJ et al. 2023 ESC Guidelines for the management of cardio vascular disease in patients with diabetes. European Heart Journal. 2023;44(39):4043–140. DOI: 10.1093/eurheartj/ehad192
26. Bottle A, Kim D, Aylin P, Cowie MR, Majeed A, Hayhoe B. Routes to diagnosis of heart failure: observational study using linked data in England. Heart. 2018;104(7):600–5. DOI: 10.1136/heartjnl-2017-312183
27. Hayhoe B, Kim D, Aylin PP, Majeed FA, Cowie MR, Bottle A. Adherence to guidelines in management of symptoms suggestive of heart failure in primary care. Heart. 2019;105(9):678–85. DOI: 10.1136/heartjnl-2018-313971
28. Pages N, Picard F, Barritault F, Amara W, Lafitte S, Maribas P et al. Re mote patient monitoring for chronic heart failure in France: When an innovative funding program (ETAPES) meets an innovative solution (Satelia® Cardio). Digital Health. 2022;8:205520762211167. DOI: 10.1177/20552076221116774
29. Rabuñal R, Suarez-Gil R, Golpe R, Martínez-García M, Gómez-Méndez R, Romay-Lema E et al. Usefulness of a Telemedicine Tool TELEA in the Management of the COVID-19 Pandemic. Tele medicine and e-Health. 2020;26(11):1332–5. DOI: 10.1089/tmj.2020.0144
30. Bouraghi H, Mohammadpour A, Khodaveisi T, Ghazisaeedi M, Saeedi S, Familgarosian S. Virtual Reality and Cardiac Diseases: A Systematic Review of Applications and Effects. Journal of Healthcare Engineering. 2023;2023(1):8171057. DOI: 10.1155/2023/8171057
Review
For citations:
Belenkov Yu.N. History and Development of the Society of Heart Failure Specialists (On the 25th Anniversary of the Society). Kardiologiia. 2024;64(11):3-14. (In Russ.) https://doi.org/10.18087/cardio.2024.11.n2839
Views:
313
Email this article 
Post a Comment 
